PGGM Investments Has $4.90 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

PGGM Investments lifted its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 19.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,537 shares of the medical research company’s stock after purchasing an additional 3,452 shares during the quarter. PGGM Investments’ holdings in Laboratory Co. of America were worth $4,895,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Trust Investment Advisors raised its position in Laboratory Co. of America by 1.8% during the fourth quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock worth $583,000 after acquiring an additional 46 shares in the last quarter. Atria Wealth Solutions Inc. raised its position in shares of Laboratory Co. of America by 2.8% in the fourth quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock valued at $448,000 after purchasing an additional 53 shares during the period. Caprock Group LLC raised its position in shares of Laboratory Co. of America by 1.8% in the fourth quarter. Caprock Group LLC now owns 3,084 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 56 shares during the period. UMB Bank n.a. grew its stake in shares of Laboratory Co. of America by 22.1% in the third quarter. UMB Bank n.a. now owns 315 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 57 shares in the last quarter. Finally, Arjuna Capital grew its stake in shares of Laboratory Co. of America by 3.2% in the third quarter. Arjuna Capital now owns 1,819 shares of the medical research company’s stock valued at $366,000 after acquiring an additional 57 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Stock Up 0.0 %

Shares of NYSE LH opened at $198.40 on Monday. Laboratory Co. of America Holdings has a 12 month low of $174.20 and a 12 month high of $234.09. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $16.69 billion, a price-to-earnings ratio of 39.92, a PEG ratio of 1.49 and a beta of 1.01. The business has a 50-day moving average of $211.70 and a 200-day moving average of $214.85.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping the consensus estimate of $3.46 by $0.22. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The company had revenue of $3.18 billion during the quarter, compared to analyst estimates of $3.12 billion. During the same quarter in the previous year, the firm earned $3.82 earnings per share. Laboratory Co. of America’s revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that Laboratory Co. of America Holdings will post 14.85 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.45%. The ex-dividend date of this dividend is Friday, May 24th. Laboratory Co. of America’s dividend payout ratio is currently 57.95%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LH shares. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a research note on Monday, March 25th. Truist Financial decreased their price target on shares of Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. SVB Leerink started coverage on shares of Laboratory Co. of America in a research note on Monday, February 26th. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, TheStreet downgraded shares of Laboratory Co. of America from a “b-” rating to a “c+” rating in a research note on Thursday, February 15th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Laboratory Co. of America presently has an average rating of “Moderate Buy” and an average price target of $243.14.

Insiders Place Their Bets

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total value of $57,513.54. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at $1,695,872.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 259 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $222.06, for a total value of $57,513.54. Following the completion of the sale, the executive vice president now owns 7,637 shares in the company, valued at $1,695,872.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $226.45, for a total value of $53,668.65. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,729,398.65. The disclosure for this sale can be found here. Insiders sold a total of 54,305 shares of company stock valued at $11,761,059 over the last quarter. 0.85% of the stock is owned by corporate insiders.

Laboratory Co. of America Company Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).